Cellectis S.A Total Liabilities 2015-2024 | CLLS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cellectis S.A total liabilities from 2015 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Cellectis S.A Total Liabilities 2015-2024 | CLLS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cellectis S.A total liabilities from 2015 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$231.2B
Amgen (AMGN)	$160B
Gilead Sciences (GILD)	$137.1B
Vertex Pharmaceuticals (VRTX)	$123.3B
Bristol Myers Squibb (BMY)	$113.2B
CSL (CSLLY)	$80.1B
GSK (GSK)	$76.6B
Regeneron Pharmaceuticals (REGN)	$76.1B
Argenex SE (ARGX)	$39.3B
Alnylam Pharmaceuticals (ALNY)	$32.5B
BioNTech SE (BNTX)	$28.3B
BeiGene (ONC)	$23.9B
Biogen (BIIB)	$20.1B
Illumina (ILMN)	$15.4B
Insmed (INSM)	$15B
Genmab (GMAB)	$14.9B
Genmab (GNMSF)	$14.7B
Incyte (INCY)	$13.8B
Intra-Cellular Therapies (ITCI)	$13.7B
BioMarin Pharmaceutical (BMRN)	$13.1B
Moderna (MRNA)	$13B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Sarepta Therapeutics (SRPT)	$10.4B
Bio-Techne Corp (TECH)	$10.4B
Vaxcyte (PCVX)	$10.3B
Exelixis (EXEL)	$9.8B
Ascendis Pharma (ASND)	$9.4B
Exact Sciences (EXAS)	$9.2B
Repligen (RGEN)	$9.1B
Bio-Rad Laboratories (BIO.B)	$8.7B